一分钟看懂
这是一项关于乳腺癌的IV 期研究，登记的药物或干预包括Ribociclib；Letrozole；Anastrozole；Goserelin；Tamoxifen；Fulvestrant，当前状态为研究进行中，已停止招募。登记地点显示中国重庆、石家庄、哈尔滨、长沙等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Ribociclib；Letrozole；Anastrozole；Goserelin；Tamoxifen；Fulvestrant · IV 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Novartis Investigative Site · 重庆
- Novartis Investigative Site · 石家庄
- Novartis Investigative Site · 哈尔滨
- Novartis Investigative Site · 长沙
- Novartis Investigative Site · 南京
- Novartis Investigative Site · 苏州
- Novartis Investigative Site · 长春
- Novartis Investigative Site · 昆明
- Novartis Investigative Site · 杭州
- Novartis Investigative Site · 北京
- Novartis Investigative Site · 青岛
- Novartis Investigative Site · 上海
- Novartis Investigative Site · 天津
公开的入选条件
- * Signed informed consent must be obtained prior to participation in the study.
- * Participant is currently participating in a Novartis sponsored global study (parent study), receiving treatment with ribociclib in combination with other drugs and the parent study has fulfilled its primary objective(s).
- * Willingness and ability to comply with scheduled visits, treatment plans and any other study procedures.
- * Participant must have been receiving treatment with ribociclib for at least 6 cycles in the parent study.
- * Participant must have evidence of clinical benefit as determined by the Investigator.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT05161195；登记信息更新于 2026-09-17。